Kategori: ASO

Start på rekruttering til ATTUNE-klinisk forsøg

ATTUNE-forsøget er en fase 1/2 klinisk undersøgelse sponsoreret af Ionis. Formålet er at evaluere ION440, en eksperimentel antisense-oligonukleotidterapi (ASO), der er udviklet til at behandle årsagen til MECP2-duplikationssyndrom (MDS).

ION440: IONIS bringer MDS-fællesskabet op på næste niveau

Written by David and verified by Ionis Following Ionis’ recent announcement about the upcoming clinical trial, we aim to provide a clearer understanding of this trial. It is especially important for families considering enrolling their child to know what a clinical trial is, particularly in the context of rare diseases like MECP2 Duplication Syndrome (MDS). […]